Despite new market entrants in the form of Gilead's Livdelzi and Ipsen's Iqirvo, US gastroenterologists report nearly half of PBC patients suffer fro ...

GSK's marketing application for linerixibat, targeting cholestatic pruritus in PBC patients, gains EMA acceptance based on phase III success.

LONDON - The European Medicines Agency has accepted GSK’s (LSE/NYSE:GSK) marketing authorization application for linerixibat, an investigational treatment for cholestatic pruritus in patients with ...

LONDON - The European Medicines Agency has accepted GSK’s (LSE/NYSE:GSK) marketing authorization application for linerixibat, an investigational treatment for cholestatic pruritus in patients with ...

The GLISTEN trial involved 238 PBC patients with moderate to severe itch across 19 countries. Linerixibat is currently not approved anywhere in the world. This article is based on a press release ...

GSK said on Monday that the European Medicines Agency has accepted its marketing authorisation application for linerixibat, an investigational treatment for cholestatic pruritus in patients with ...

GSK (NYSE:GSK) today announced a significant step forward in the potential treatment of cholestatic pruritus in patients with primary biliary cholangitis (PBC), a rare autoimmune liver disease. The ...